The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus.
The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus.
复制标题
DOI：
10.1038/s41598-022-16677-3
复制
发表时间：
2022-07-20
影响因子：
4.6
通讯作者：
Christou, Niki
中科院分区：
文献类型：
--
作者：
Tarhini, Zeinab;Manceur, Kamelia;Magne, Julien;Mathonnet, Muriel;Jost, Jeremy;Christou, Niki
先前研究的证据表明二甲双胍对结直肠癌 (CRC) 患者具有保护作用。本研究的目的是探讨二甲双胍的使用与患有 2 型糖尿病 (DM) 的 CRC 患者的总生存期 (OS) 和无病生存期 (DFS) 之间的关联。我们回顾性纳入了 2005 年至 2019 年间在利摩日大学医院接受结直肠癌手术并诊断为 2 型糖尿病的患者。从电子病历中收集有关患者特征、CRC、合并症和药物暴露的数据。暴露是二甲双胍的使用，结果是 OS 和 DFS。我们确定了 290 名 CRC 患者患有 2 型糖尿病。其中共有 144 人（49.7%）接受二甲双胍治疗。与非使用者相比，二甲双胍使用者明显更年轻，体重指数更高，糖尿病相关并发症更少。二甲双胍使用者的 2 年 OS 显着高于非使用者（86.9±2.9% vs. 71.0±4.0%，p=0.001）。在多变量分析中，二甲双胍的使用与更好的 OS（调整后风险比 [aHR] = 0.45 95% 置信区间 [95% CI]：0.21–0.96）和更好的 DFS（aHR = 0.31；95% CI：0.18–0.54）相关。总之，使用二甲双胍可以改善患有 2 型糖尿病的 CRC 患者的 OS 和 DFS。
Evidence from previous studies suggests a protective effect of metformin in patients with colorectal cancer (CRC). The aim of this study was to examine the associations between metformin use and overall survival (OS) and disease-free survival (DFS) in CRC patients with type 2 diabetes mellitus (DM). We retrospectively included patients who underwent surgery for CRC at Limoges’ University Hospital between 2005 and 2019 and diagnosed with type 2 DM. Data on the characteristics of patients, CRC, comorbidities and drug exposure were collected from the electronic medical records. The exposure was the use of metformin and the outcomes were OS and DFS. We identified 290 CRC patients with type 2 DM. A total of 144 (49.7%) of them were treated with metformin. Metformin users were significantly younger, with higher body mass index and less diabetes-related complications compared to non-users. The 2-year OS was significantly higher in metformin users than in non-users (86.9 ± 2.9% vs. 71.0 ± 4.0%, p = 0.001). In multivariate analysis, metformin use was associated with better OS (adjusted hazard ratios [aHR] = 0.45 95% confidence interval [95% CI]: 0.21–0.96) and better DFS (aHR = 0.31; 95% CI: 0.18–0.54). In conclusion, the use of metformin may improve OS and DFS in CRC patients with type 2 DM.
登录
查看更多内容
影响因子：
2
作者：
Wang Y;Wu Z;Hu L
通讯作者：
Hu L
影响因子：
3.7
作者：
Valaee S;Yaghoobi MM;Shamsara M
通讯作者：
Shamsara M
影响因子：
6.4
作者：
Lee, Jin Ha;Kim, Tae Il;Kim, Won Ho
通讯作者：
Kim, Won Ho
EMT，癌症干细胞和耐药性：癌症战争中新兴的邪恶轴。
影响因子：
8
作者：
Singh, A.;Settleman, J.
通讯作者：
Settleman, J.
影响因子：
--
作者：
Del Barco S;Vazquez-Martin A;Cufí S;Oliveras-Ferraros C;Bosch-Barrera J;Joven J;Martin-Castillo B;Menendez JA
通讯作者：
Menendez JA